trans-DL-1,2-Cyclopentanedicarboxylic Acid CAS 1461-97-8 Purity >97.0% Gliclazide Intermediate Factory

Short Description:

Name: trans-DL-1,2-Cyclopentanedicarboxylic Acid

CAS: 1461-97-8

Purity: >97.0%

Appearance: White to Off-White Crystalline Powder

Intermediate of Gliclazide (CAS: 21187-98-4)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of trans-DL-1,2-Cyclopentanedicarboxylic Acid (CAS: 1461-97-8) with high quality, commercial production. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available, strong after-sale service. Please contact: alvin@ruifuchem.com

Chemical Properties:

Chemical Name	trans-DL-1,2-Cyclopentanedicarboxylic Acid
Synonyms	trans-1,2-Cyclopentanedicarboxylic Acid; trans-Cyclopentane-1,2-Dicarboxylic Acid
CAS Number	1461-97-8
CAT Number	RF-PI1819
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C7H10O4
Molecular Weight	158.15
Melting Point	163.0~165.0℃ (lit.)
Density	1.396±0.06 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Inspection Standard	Results
Characteristics	White to Off-White Crystalline Powder	Conforms
Loss on Drying	<0.50%	0.10%
Purity	>97.0%	97.6%
Test Standard	Enterprise Standard
Usage	Intermediate of Gliclazide (CAS: 21187-98-4)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

trans-DL-1,2-Cyclopentanedicarboxylic Acid (CAS: 1461-97-8) is an intermediate of Gliclazide (CAS: 21187-98-4). Gliclazide is the second generation of sulfonylurea oral hypoglycemic agents for adults with type 2 diabetes mellitus, diabetes mellitus with obesity or vascular disease. Gliclazide has the dual functions of lowering blood sugar and improving coagulation function. Gliclazide can not only improve the metabolism of diabetic patients, but also improve or delay the occurrence of diabetic vascular complications.